CD38 and plasma cell myeloma: Additional studies demonstrated that treatment with daratumumab not only directly kills myeloma cells but also causes the depletion of CD38+ immunosuppressive cells like myeloid derived suppressor cells (MDSCs) and Tregs, relieving local immunosuppression and improving the cytotoxic CD8+ immune response [68].